SCOTT ROCKLAGE LEADERSHIP JOURNEY
Scott Rocklage is based in Waltham, MA office and currently serves as a managing partner at 5AM Ventures. He received a Bachelor of Science from the University of California in Chemistry. Rocklage attended the Massachusetts Institute of Technology for a Ph.D. in Chemistry. He conducted research in Richard R. Schrock’s laboratory Nobel Prize 2005 in Chemistry. In 2003, Rocklage teamed up with 5AM Ventures as a venture partner and in 2004 he went on to become a managing partner.
Dr. Scott Rocklage has three decades experience in healthcare management. His leadership responsibilities led to approval of three US Drug applications by FDA. Through clinical trials, he has had a chance to enter a number of drug candidates. Rocklage is currently serving as the Chair of Relypsa, Semprus Bioscience Corp, Novira Therapeutics, and Achaogen. He also serves in WaveRX, Variation, Kinestral, Nouscom AG and Pulmatrix Boards. He is on the Board of Associates at the White Head Institute.
To bring ideas to reality either Dr. Rocklage works with entrepreneurs’ business executives, scientists or physicians to help them to shape their concepts into probable medicines to treat unmet needs in the medical field. He has contributed to the trend of explosive growth targeting at specific genotypes and mutation in treating cancer in a unique way.
Dr. Rocklage is keen on prioritization, time management and calendaring. Given a fresh start, he would focus on team selection from the initial stage. He encourages entrepreneurs to be bold in risk-taking. For 5AM Ventures growth he has stayed true to the company strengths and focusing on what the company does best.
Rocklage previous positions held
Scott Rocklage has served at EPIRUS Biopharmaceuticals Inc. as the chief executive officer, at Amersham Health as the chief executive officer and at Llypsa as a co-president. He has served as the chief executive officer, chair, and president at NycomedSalutar Inc. He has served at Cubist Pharmaceuticals Inc. as the president between July 1994 and March 2001. Since 2013, Dr. Rocklage has served as the Chairman of the Board of Cidara Therapeutics. He has served in various R&D capacities at Catalytic and Salutar. He has over 100 peers reviewed publications and a co-inventor and inventor with over 30 U.S patents.
To learn more, visit https://ideamensch.com/scott-rocklage/.